Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3860244
Reference Type
Journal Article
Title
Brief Report: Plasma Concentrations of Perfluorooctane Sulfonamide and Time-to-pregnancy Among Primiparous Women
Author(s)
Whitworth, KW; Haug, LS; Sabaredzovic, A; Eggesbo, M; Longnecker, MP
Year
2016
Is Peer Reviewed?
Yes
Journal
Epidemiology
ISSN:
1044-3983
EISSN:
1531-5487
Volume
27
Issue
5
Page Numbers
712-715
Language
English
PMID
27276029
DOI
10.1097/EDE.0000000000000524
Web of Science Id
WOS:000381011000021
Abstract
BACKGROUND:
A previous study reported a negative association between perfluorooctane sulfonamide (PFOSA) concentrations and fecundability.
METHODS:
We examined this association among women enrolled in the Norwegian Mother and Child Cohort Study (MoBa), in 2003-2004. This analysis was restricted to 451 primiparous women to avoid bias due to previous pregnancy. Self-reported time-to-pregnancy (TTP) and plasma were obtained around 18 weeks of gestation. Approximately half of the women had measurable PFOSA levels; missing values were multiply imputed. We used the logistic analogue of discrete-time survival analysis to examine the adjusted association between PFOSA, other perfluoroalkyl substances, and TTP.
RESULTS:
The median-measured PFOSA concentration was 0.03 ng/ml (interquartile range = 0.02, 0.07). The age and body mass index-adjusted association between an interquartile distance increase in PFOSA and TTP was 0.91 (95% confidence interval = 0.71, 1.17). Imputation of missing PFOSA resulted in similar estimates. No association was observed with other perfluoroalkyl substances.
CONCLUSION:
Based on a weakly decreased fecundability odds ratio, we found only limited support for an association between plasma PFOSA concentrations and TTP among primiparous women. See Video Abstract at http://links.lww.com/EDE/B79.
Tags
PFAS
•
Additional PFAS (formerly XAgency)
Literature Search November 2019
Other Sources
Reference list review of included studies
TEDX
Screened Studies
Excluded
Exclude (TIAB)
•
Expanded PFAS SEM (formerly PFAS 430)
Litsearch: September 2019
PubMed
Web of Science
Other Sources
PFAS TOX Database
Screened Studies
Excluded
Exclude (TIAB)
Not prioritized for screening
Perfluorooctane
•
^Per- and Polyfluoroalkyl Substances (PFAS)
PFOSA (754-91-6)
Literature Search
Pubmed
WOS
•
PFAS 150
Literature Search Update December 2020
PubMed
WOS
Literature Search August 2019
PubMed
Web of Science
Other sources
PFAS TOX Database
Screened Studies
Included
Include (TIAB)
Include (Full Text)
Perfluorinated compounds
Perfluorooctane
Perfluorooctanesulfonamide
Perfluorooctanesulfonamide sodium salt (1:1)
•
PFDA
June 2022 Pelch Database
Submitted to EPA
•
PFHxS
Database searches
Pelch PFAS SEM
Excluded
TiAb
Literature Search Update April 2023
Included Met PECO
•
PFNA
June 2022 Pelch Database
•
PFOSA
Literature Search
Pubmed
WOS
Screening Results
Human/Epi studies
Repro tox
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity